Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL29253571 | 1.00 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL663145 | 1.00 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL9109080 | 1.00 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL3682796 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL9692462 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL204687 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL529510 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL2301332 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL9692471 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL29391563 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4486730-A1 | PROCESSES FOR THE PREPARATION OF PHENYLTETRAHYDROFURAN COMPOUNDS | Genentech Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| WO-2023164679-A1 | PROCESSES FOR THE PREPARATION OF PHENYLTETRAHYDROFURAN COMPOUNDS | GENENTECH, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | INCYTE HOLDINGS CORPORATION (US) | 2021-04-13 | — | — | US | claimed |
| WO-2017044043-A1 | PROCESS FOR DIRECT AMIDATION OF AMINES VIA RH(I)-CATALYZED ADDITION OF BOROXINES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-03-16 | — | — | WO | claimed |
| US-20110288297-A1 | Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis | PFIZER, INC. (US) | 2011-11-24 | — | — | US | claimed |
| EP-1913000-A2 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES; THEIR INTERMEDIATES AND SYNTHESIS | Pfizer Products Inc. (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007012953-A2 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES; THEIR INTERMEDIATES AND SYNTHESIS | PFIZER PRODUCTS INC. (US) | 2007-02-01 | — | — | WO | claimed |
| EP-3541825-B1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | IDENIX PHARMACEUTICALS LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12559504-B2 | Benzotriazole derivative | UBE CORPORATION (JP) | 2026-02-24 | — | — | US | disclosed |
| US-RE50724-E1 | 4-membered ring carboxamides used as nematicides | SYNGENTA CROP PROTECTION AG (CH) | 2026-01-06 | — | — | US | disclosed |
| EP-3978073-B1 | 1H-BENZO[D][1,2,3]TRIAZOLE DERIVATIVES AS KEAP1 INHIBITORS FOR THE TREATMENT OF RENAL DISEASES | UBE CORP (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-20250122160-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| US-12129249-B2 | Method for producing optically active compound | DAY ONE BIOPHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-6242377-B1 | POLYMERIZATION IN PRESENCE OF BISOXAZOLINE WITH NICKEL, COBALT, PALLADIUM, RHODIUM, RUTHENIUM, ALUMINUM AND BORON COMPLEXES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-1063226-A1 | Process for the preparation of N-acyl-amino acids | Degussa-Hüls Aktiengesellschaft (DE) | 2000-12-27 | — | — | EP | disclosed |
| US-6043387-A | USEFUL AS KEY COMPONENTS IN CATALYSTS FOR ASYMMETRIC REACTIONS, PROVIDING DESIRABLY HIGH ENANTIOMERIC EXCESS | MERCK & CO., INC. (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0942010-A1 | Transition metal compounds, catalyst components and catalysts for olefin polymerization, and process for producing olefinic polymers | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-09-15 | — | — | EP | disclosed |
| US-5874629-A | TREATING RACEMIC PHOSPHINYL DERIVATIVE WITH DIBENZOYL-L-TARTARIC ACID A RESOLVING AGENT TO FORM ISOMERS, REDUCING TO PRODUCE CHIRAL BISPHOSPHINES; USED AS CATALYST FOR ASYMMETRIC REACTIONS | MERCK & CO., INC. (US) | 1999-02-23 | — | — | US | disclosed |
| US-5401857-A | Process for making γ-butyrolactones | ARCO CHEMICAL TECHNOLOGY, L.P. (US) | 1995-03-28 | — | — | US | disclosed |
| US-5401856-A | Carbonylation of allylmethylamine | ARCO CHEMICAL TECHNOLOGY, L.P. (US) | 1995-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559504-B2 | Benzotriazole derivative | KEAP1, NFE2L2, NCOR1 | GPR3 1749/4885CA1 4424/4885CA2 3070/4885 |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | JAK1, JAK3, JAK2 | GPR3 2065/4885CA1 4747/4885CA2 4617/4885 |
| US-20250122160-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | GPR3 4163/4885CA1 4547/4885CA2 2713/4885 |
| US-20110288297-A1 | Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis | DPYD, CPS1, TYMS | GPR3 2674/4885CA1 1907/4885CA2 1119/4885 |
| US-12129249-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | GPR3 3866/4885CA1 4105/4885CA2 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.